Clinical Trial Update: Safety Study of GC1118 (Recombinant Human Anti-EGFR Antibody) in Patients With Advanced Solid Cancer [Phase 1]

View source ↗

Summary

Phase 1 safety study update for GC1118, a recombinant human anti-EGFR antibody, in advanced solid cancers including gastric and colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Gastric Cancer

Drugs mentioned

• GC1118 (recombinant human anti-EGFR antibody)

Snippet

Sponsor: Green Cross Corporation | Conditions: Neoplasm Metastasis, Gastric Cancer | Phase 1 | Status: UNKNOWN